Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases

被引：0

作者：

Kavgaci, Akif ^{[1
]}

Kula, Serdar ^{[1
]}

Incedere, Fatma ^{[1
]}

Terlemez, Semiha ^{[1
]}

Tunaoglu, Fatma Sedef ^{[1
]}

机构：

[1] Gazi Univ, Fac Med, Dept Pediat, Div Pediat Cardiol, Ankara, Turkiye

来源：

TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | 2023年 / 31卷 / 01期

关键词：

Pulmonary arterial hypertension; subcutaneous; treprostinil;

D O I：

10.5606/tgkdc.dergisi.2023.23748

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-related symptoms, or in cases where epoprostenol treatment should be reduced due to side effects. In this article, we describe three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used.

引用

页码：145 / 148

页数：4

共 50 条

[21] Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension
Laura Mori, Ana
Rodriguez, Andrea
Alberto Gagliardi, Juan
Stewart Harris, Alejandro
EUROPEAN HEART JOURNAL-CASE REPORTS, 2021, 5 (10)
[22] Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension
Olsson, Karen M.
Richter, Manuel J.
Kamp, Jan C.
Gall, Henning
Heine, Alexander
Ghofrani, Hossein-Ardeshir
Fuge, Jan
Ewert, Ralf
Hoeper, Marius M.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (07) : 748 - 756
[23] Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
Desole, Susanna
Richter, Manuel Jonas
Heine, Alexander
Ewert, Ralf
PULMONARY CIRCULATION, 2018, 9 (01)
[24] Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension
Harutyunova, Satenik
Benjamin, Nicola
Eichstaedt, Christina
Marra, Alberto M. M.
Xanthouli, Panagiota
Nagel, Christian
Gruenig, Ekkehard
Egenlauf, Benjamin
RESPIRATION, 2023, 102 (08) : 579 - 590
[25] Using the upper buttocks as a subcutaneous site for treprostinil infusion in children with pulmonary artery hypertension
Ono, Hiroshi
Yotani, Nobuyuki
Kato, Hitoshi
CARDIOLOGY IN THE YOUNG, 2020, 30 (07) : 1024 - 1025
[26] Chryseomonas luteola bloodstream infection in a pediatric patient with pulmonary arterial hypertension receiving intravenous treprostinil therapy
A. Y. Wen
I. K. Weiss
R. B. Kelly
Infection, 2013, 41 : 719 - 722
[27] A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension
Coons, James C.
Crisamore, Karryn
Adams, Solomon
Modany, Ashley
Simon, Marc A.
Zhao, Wenchen
Shaik, Imam H.
Venkataramanan, Raman
Empey, Philip E.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2021, 15
[28] Clinical impact of subcutaneous treprostinil in trisomy 21 patient with pulmonary arterial hypertension associated with CHD
Numata, Ryusuke
Takigiku, Kiyohiro
Takei, Kouta
CARDIOLOGY IN THE YOUNG, 2022, 32 (09) : 1502 - 1504
[29] Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
Bourge, Robert C.
Tapson, Victor F.
Safdar, Zeenat
Benza, Raymond L.
Channick, Richard N.
Rosenzweig, Erika B.
Shapiro, Shelley
White, Richard James
McSwain, Christopher Shane
Gotzkowsky, Stephen Karl
Nelsen, Andrew C.
Rubin, Lewis J.
CARDIOVASCULAR THERAPEUTICS, 2013, 31 (01) : 38 - 44
[30] Chryseomonas luteola bloodstream infection in a pediatric patient with pulmonary arterial hypertension receiving intravenous treprostinil therapy
Wen, A. Y.
Weiss, I. K.
Kelly, R. B.
INFECTION, 2013, 41 (03) : 719 - 722

← 1 2 3 4 5 →